Mitochondria and peroxisomes are the major endogenous sources of ROS
If weight is coming off consistently, appetite is well controlled and side effects are manageable, there is generally no clinical reason to increase ahead of schedule
The review further distinguishes between established outcome benefits (CVD, CKD, and OSA) and conditions still under investigation (neurodegeneration, arthritis, and some liver endpoints)
To do that well, your anesthesiologist needs to know your medication, dose, and phase of treatment along with any gastrointestinal symptoms or other medical conditions that slow digestion
The week-by-week timeline for tirzepatide follows a similar pattern but reaches higher total weight loss by the end of the treatment period